VolitionRX (VNRX) Expected to Announce Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is projected to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect VolitionRX to post earnings of ($0.73) per share and revenue of $1.5190 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

VolitionRX Stock Up 13.2%

Shares of NYSEAMERICAN:VNRX opened at $2.32 on Wednesday. The company’s 50 day moving average price is $3.42 and its two-hundred day moving average price is $5.07. VolitionRX has a 12-month low of $2.01 and a 12-month high of $18.80. The firm has a market cap of $18.77 million, a PE ratio of -0.53 and a beta of 1.03.

Wall Street Analyst Weigh In

VNRX has been the topic of a number of analyst reports. HC Wainwright decreased their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Finally, Citigroup lowered shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, VolitionRX has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC boosted its position in shares of VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of VolitionRX during the 4th quarter worth approximately $34,000. Jane Street Group LLC acquired a new stake in shares of VolitionRX during the 4th quarter worth approximately $28,000. Finally, Geode Capital Management LLC boosted its position in shares of VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.